MX9701600A - Derivados de naftiridina novedosos y composicion medicinal de los mismos. - Google Patents

Derivados de naftiridina novedosos y composicion medicinal de los mismos.

Info

Publication number
MX9701600A
MX9701600A MX9701600A MX9701600A MX9701600A MX 9701600 A MX9701600 A MX 9701600A MX 9701600 A MX9701600 A MX 9701600A MX 9701600 A MX9701600 A MX 9701600A MX 9701600 A MX9701600 A MX 9701600A
Authority
MX
Mexico
Prior art keywords
diseases
naphthyridine derivative
medicinal composition
novel naphthyridine
novel
Prior art date
Application number
MX9701600A
Other languages
English (en)
Inventor
Kazuhisa Takayama
Masahiro Iwata
Yoshinori Okamoto
Motonori Aoki
Akira Niwa
Yasuo Isomura
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of MX9701600A publication Critical patent/MX9701600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un derivado de 1,8-naftiridina representado por la formula general (I), y una sal, hidrato, y solvato del mismo, el compuesto inhibe las fosfodiesterasas tipo IV, y es util como un preventivo o remedio para enfermedades respiratorias, enfermedades inflamatorias, enfermedades de las articulaciones sistémicas o locales, enfermedades proliferativas, inflamaciones que acompañan al trasplante de organos, enfermedades asociadas con la urinacion, y enfermedades en donde participan factores de necrosis tumoral (TNF) y otras citocinas, tales como Il-1 o IL-2. (Ver Formula).
MX9701600A 1994-08-29 1995-08-28 Derivados de naftiridina novedosos y composicion medicinal de los mismos. MX9701600A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP20367794 1994-08-29
JP1911395 1995-02-07
PCT/JP1995/001700 WO1996006843A1 (en) 1994-08-29 1995-08-28 Novel naphthyridine derivative and medicinal composition thereof

Publications (1)

Publication Number Publication Date
MX9701600A true MX9701600A (es) 1997-05-31

Family

ID=26355930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701600A MX9701600A (es) 1994-08-29 1995-08-28 Derivados de naftiridina novedosos y composicion medicinal de los mismos.

Country Status (10)

Country Link
US (1) US5817670A (es)
EP (1) EP0779292A4 (es)
KR (1) KR970705562A (es)
CN (1) CN1043993C (es)
AU (1) AU3265695A (es)
CA (1) CA2197984A1 (es)
HU (1) HUT76980A (es)
MX (1) MX9701600A (es)
NZ (1) NZ291507A (es)
WO (1) WO1996006843A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268190A1 (en) * 1997-08-06 1999-02-18 Suntory Limited 1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor
CN1156476C (zh) 1998-01-29 2004-07-07 第一三得利制药株式会社 作为ⅳ型磷酸二酯酶抑制剂的1-环烷基-1,8-二氮杂萘-4-酮衍生物
AU8562198A (en) * 1998-08-10 2000-03-06 Kyorin Pharmaceutical Co. Ltd. Remedies for multiple sclerosis
OA11591A (en) * 1998-08-11 2004-07-30 Pfizer Prod Inc Substituted 1,8-naphthyridin-4(H)-ones as phosphodiesterase 4 inhibitors.
CZ302882B6 (cs) 1999-08-21 2012-01-04 Nycomed Gmbh Farmaceutický prostredek
TWI262919B (en) * 1999-10-25 2006-10-01 Yamanouchi Pharma Co Ltd Naphthyridine derivative
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US7868015B2 (en) * 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
JP4524072B2 (ja) * 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
JP4166991B2 (ja) * 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
EP1389467B1 (en) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
JP4510384B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 骨折治癒促進用組成物
JP4294469B2 (ja) * 2001-06-12 2009-07-15 あすか製薬株式会社 Ｐｄｅｉｖ阻害剤
KR20040041177A (ko) * 2001-09-26 2004-05-14 바이엘 파마슈티칼스 코포레이션 당뇨병 치료제로서의 1,6-나프티리딘 유도체
MXPA04010267A (es) * 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
AU2003277562B2 (en) * 2002-11-06 2009-03-26 Aska Pharmaceutical Co., Ltd. Pyrazolonaphthyridine derivative
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
EP1596860A4 (en) * 2003-02-14 2009-05-27 Smithkline Beecham Corp NEW CONNECTIONS
WO2004087880A2 (en) * 2003-03-26 2004-10-14 Bayer Pharmaceuticals Corporation Compounds and their use to treat diabetes and related disorders
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
EP1628682B1 (en) * 2003-05-22 2013-09-25 Takeda GmbH Composition comprising a pde4 inhibitor and a pde5 inhibitor for the treatment of copd
AU2004269923B2 (en) * 2003-09-05 2010-05-13 Takeda Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
JPWO2005049087A1 (ja) * 2003-11-20 2007-06-07 アステラス製薬株式会社 慢性骨盤痛症候群治療剤
US20050169894A1 (en) * 2003-11-26 2005-08-04 Geliebter David M. Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of Type III and/or Type IV phosphodiesterases
US20050201989A1 (en) * 2004-02-19 2005-09-15 St. Camillus Medical, Inc. Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of tumor necrosis factor-alpha
US8017633B2 (en) 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
PE20061193A1 (es) * 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
US20080096905A1 (en) * 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
US20090137550A1 (en) * 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
CN101268073B (zh) 2005-09-15 2011-10-19 Aska制药株式会社 杂环化合物、制备方法及其用途
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
US8426673B2 (en) 2008-01-11 2013-04-23 Astellas Pharma, Inc. Pathological animal model for pelvic pain syndrome
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
EP2318407B1 (en) 2008-07-23 2013-01-02 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
JP5631310B2 (ja) 2008-07-23 2014-11-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 三環式ピラゾロピリジンキナーゼ阻害剤
CA2732765A1 (en) * 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010129668A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
MX2012008643A (es) 2010-01-27 2013-02-26 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
CN102869663A (zh) 2010-01-27 2013-01-09 沃泰克斯药物股份有限公司 吡唑并吡嗪激酶抑制剂
US9067932B2 (en) 2010-01-27 2015-06-30 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150050626A1 (en) * 2013-03-15 2015-02-19 Dart Neuroscience, Llc Systems, Methods, and Software for Improving Cognitive and Motor Abilities
US10822299B2 (en) 2016-05-26 2020-11-03 The Regents Of The University Of California Compounds and methods for hematopoietic regeneration
CN108658937A (zh) * 2017-03-28 2018-10-16 中国海洋大学 一种双环生物碱类化合物及其制备方法和应用
BR112020005934A2 (pt) 2017-09-28 2020-10-06 Nanjing Transthera Biosciences Co., Ltd. inibidor de pde9 e uso do mesmo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55164682A (en) * 1979-06-11 1980-12-22 Yamanouchi Pharmaceut Co Ltd 1-alkyl-2-oxo-2h-1,8-naphthyridine derivative and its preparation
DE3368929D1 (de) * 1982-04-26 1987-02-12 Schering Corp 1,8-naphthyridine and 1,5,8-azanaphthyridine derivatives
US4775686A (en) * 1986-10-15 1988-10-04 Schering Corporation Naphthyridine derivatives and method for treating allergic reactions
EP0267691A3 (en) * 1986-10-15 1989-08-23 Schering Corporation Use of 1-substituted naphthyridine and pyridopyrazine derivatives for the preparation of medicaments with immunosuppressor activity.
JPS63159382A (ja) * 1986-10-15 1988-07-02 シェリング・コーポレーション １−置換ナフチリジンおよびピリドピラジン誘導体
DK0612321T3 (da) * 1991-10-09 1999-12-13 Syntex Inc Pyridopyridazinon- og pyridazinthionforbindelser med PDE IV inhiberende aktivitet
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
EP0670320A4 (en) * 1992-12-01 1997-05-02 Green Cross Corp 1,8-NAPHTHYRIDIN-2-ON DERIVATIVE AND ITS USE.
JPH0710875A (ja) * 1993-06-21 1995-01-13 Green Cross Corp:The 選択的ホスホジエステラーゼｉｖ阻害剤

Also Published As

Publication number Publication date
CN1043993C (zh) 1999-07-07
NZ291507A (en) 1997-12-19
US5817670A (en) 1998-10-06
HUT76980A (hu) 1998-01-28
EP0779292A1 (en) 1997-06-18
EP0779292A4 (en) 1997-09-24
WO1996006843A1 (en) 1996-03-07
CN1156455A (zh) 1997-08-06
CA2197984A1 (en) 1996-03-07
AU3265695A (en) 1996-03-22
KR970705562A (ko) 1997-10-09

Similar Documents

Publication Publication Date Title
MX9701600A (es) Derivados de naftiridina novedosos y composicion medicinal de los mismos.
LUC00155I1 (es)
EP0395328A3 (en) Penylpyrimidone derivates and their use as therapeutic agents
AU561633B2 (en) Tablet with a slow or zero order release rate
CA2258285A1 (en) Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
HRP950338B1 (en) New thrombin inhibitors, their preparation and use
AU635984B2 (en) New isoindolone derivatives and their preparation
AU1069001A (en) Quinuclidine acrylamides
AU690598B2 (en) Retinoid-like compounds
CA2102179A1 (en) Quinuclidine derivatives
EP0535529A3 (en) Indole derivatives and anti-ulcer compositions
DE3276433D1 (en) Novel ergolinyl compounds nitrogen-substituted in the 8-position, their preparation, and use as medicinal agents
AU6048086A (en) Bactericidal formulations for use in the area of veterinary medicine
TW261616B (es)
ATE38991T1 (de) In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
DE59209327D1 (de) 2- 3-(4-amidino-phenyl)]-propionsäurederivate, ihre herstellung und verwendung
TW429148B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
Shriver et al. Pharmacology of rioprostil, a new gastric cytoprotective/antisecretory agent
CA2168193A1 (en) Aryalkyl-thiadiazinones
EP0201349A3 (en) Tetrazole derivatives
EP0653209A4 (en) Remedy for inflammatory intestinal diseases.
AU557880B2 (en) Method for modulating the immune response with dibenzocycloheptenylidenes
AU3306884A (en) Substituted pyrido(1,2-c)imidazo(1,2-a) benzimidazoles
AU674909B2 (en) New triazoloquinazolines, their production and their use
ES8401488A1 (es) Procedimiento de preparacion de derivados de diaza-3,7a-cicloherta-(j,k)-fluorenos.